Aviv HBOT: Protocol, Evidence and What to Expect

Aviv HBOT is not a standard hyperbaric oxygen treatment. It is a specific clinical protocol developed by the research group at the Sagol Center for Hyperbaric Medicine at Shamir Medical Center in Israel, led by Prof. Shai Efrati. What distinguishes it from conventional HBOT is the deliberate alternation of oxygen concentration during each session, a technique that exploits what researchers call the hyperoxic-hypoxic paradox.

The hypothesis behind the protocol is that alternating between high oxygen and normal air at a fixed pressure of 2.0 ATA stimulates cellular responses more powerfully than maintaining constant high oxygen. The intermittent oxygen drops create brief hypoxic stress signals that activate mitochondrial adaptation, growth factor release, and angiogenesis in ways that steady-state hyperoxia may not.

Understanding the Aviv HBOT Mechanism

A standard HBOT session delivers 100% oxygen at elevated pressure for the entire session duration. The Aviv protocol differs by alternating between 100% oxygen and normal compressed air during the same session, typically switching every 20 minutes at 2.0 ATA. This creates repeated cycles of hyperoxia and relative hypoxia within a single treatment.

The theoretical basis comes from research showing that the transition from hyperoxia back toward normoxia generates reactive oxygen species (ROS) signaling that activates HIF-1 alpha (hypoxia-inducible factor), VEGF (vascular endothelial growth factor), and mitochondrial biogenesis pathways.¹ These are the same pathways activated by exercise-induced hypoxia, which is why researchers describe the effect as analogous to interval training for cells.

The key distinction from soft-shell portable chambers is pressure. The Aviv protocol operates at a hard 2.0 ATA (atmospheres absolute) in a medical-grade hard chamber. Soft portable chambers sold for home use reach 1.3 to 1.5 ATA and deliver ambient air, not 100% oxygen. The pressure difference is not minor. At 2.0 ATA, dissolved oxygen in plasma increases substantially. At 1.3 ATA, the increase is modest. The published Efrati group research uses 2.0 ATA and cannot be extrapolated to lower-pressure consumer devices.

The Published Clinical Evidence

The Efrati group has published multiple peer-reviewed trials using this protocol. These are the foundational studies:

Cognitive Enhancement Findings

The most rigorously tested application of the Aviv protocol is cognitive enhancement in aging adults. A 2020 randomized controlled trial enrolled 63 healthy adults over age 64 and assigned them to 60 HBOT sessions or a control group over 3 months.²

The HBOT group showed significant improvements in global cognitive function (p=0.0017) with large effect sizes for attention (0.745) and information processing speed (0.788). MRI perfusion imaging confirmed increased cerebral blood flow to prefrontal and parietal regions. These are the brain areas most affected by age-related cognitive decline, and the improvements were on objective neuropsychological tests, not self-reported questionnaires.

The mechanism involves increased cerebral blood flow, angiogenesis (new vessel formation), neuroplasticity signaling via BDNF upregulation, and reduced neuroinflammation. Brain imaging in this trial showed new areas of increased perfusion in multiple prefrontal and parietal regions following treatment.

Anti-Aging and Telomere Data

A prospective trial from the same group published in the same year measured telomere length and senescent cell counts in 35 healthy adults over 64 before, during, and after 60 HBOT sessions at 2.0 ATA.³

Telomere length increased by more than 20% across T helper, T cytotoxic, NK, and B cells. B cells showed the most dramatic increase, with a 29.4% gain by session 60 (p=0.0001). Senescent T helper cells decreased by 37.3% (p<0.0001). A follow-up trial using the same cohort measured gene expression changes and found 1,912 genes differentially expressed after 60 sessions, including genes associated with immune senescence and cellular aging pathways.

These are the most striking published findings associated with the Aviv protocol and the ones that generated the most media attention. The important caveat: this study had no sham control, a small sample (n=35), and measured blood cell biomarkers rather than clinical outcomes. Longer telomeres in isolated blood cells may or may not translate to longer healthspan or reduced disease incidence. Independent replication of these findings has not yet been published.

What Are the Side Effects and Risks?

Aviv HBOT at 2.0 ATA has a well-documented safety profile across the Efrati group’s published trials. Adverse events in published trials were predominantly minor: ear barotrauma (most common), temporary myopia, and transient fatigue or dizziness during the oxygen-switching phase. Oxygen toxicity seizures are rare at 2.0 ATA, estimated at approximately 1 in 10,000 sessions across standard HBOT literature.

Absolute contraindications include untreated pneumothorax and certain chemotherapy drugs. Relative contraindications include claustrophobia, middle ear or sinus disease, and history of seizures. All Aviv protocol treatments require medical evaluation before starting and ongoing monitoring during sessions. This is not a consumer wellness product. It is a clinical protocol administered in specialized facilities with trained medical staff.

Protocol Structure

Each session runs approximately 90 minutes including pressurization and depressurization. Active treatment time is roughly 60 minutes with the oxygen switching cycle. The sequence and timing of the oxygen cycles follows a defined protocol and cannot be replicated by a patient adjusting their own home chamber settings.

Limitations and Ongoing Questions

The Efrati group has produced compelling data, but the scientific community’s standard for generalizability requires independent replication. All of the landmark cognitive aging, telomere, and physical performance findings come from a single research group. This does not invalidate the work, but it means the findings should be understood as strong preliminary evidence awaiting confirmation, not established medical consensus.

Additionally, the Aviv clinic model operates commercially, with the clinic providing a premium longevity service at significant cost. This does not mean the research is biased, but it is relevant context for evaluating the enthusiasm with which findings are communicated publicly.

For patients and practitioners, the most defensible position is: the Aviv protocol has produced the most rigorous HBOT research on cognitive aging published to date, the findings are clinically significant if replicated, and anyone pursuing this treatment should do so at a properly supervised medical facility using a hard chamber at 2.0 ATA, not a home soft-shell unit.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website